Pharmaceutical Technology

JUNE 20, 2023

The World Health Organisation (WHO) has granted an emergency use listing (EUL) to SK bioscience’s Covid-19 vaccine, SKYCovione. SKYCovione is a self-assembled nanoparticle vaccine and the 12th Covid-19 vaccine to receive a EUL from the regulator.

Vaccine 363

Vaccine Vaccination Protein Clinical Trials 363

Pharmaceutical Technology

DECEMBER 7, 2022

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccine 264

Vaccine Vaccination Protein Clinical Trials 264

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 11, 2024

Using viruses that infect bacteria to detect proteins sprouted by a notorious parasite, scientists have honed in on possible vaccine targets for schistosomiasis, a neglected tropical disease that currently affects an estimated 600 million people worldwide, causing 280,000 deaths per year.

Vaccine 240

Vaccine Vaccination Bacteria Protein 240

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain.

Vaccine 263

Vaccine Vaccination Clinical Trials Clinical Trials 263

Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. This means that the vaccine works against multiple serotypes of the disease, she explains. A one-size-fits-all approach.

Vaccine 299

Vaccine Vaccination Bacteria Protein 299

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccine 293

Vaccine Vaccination Antibody Trials 293

Pharmaceutical Technology

SEPTEMBER 7, 2022

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.

Vaccine 263

Vaccine Vaccination Clinical Trials Clinical Trials 263

Pharmaceutical Technology

SEPTEMBER 5, 2022

The National Medical Products Administration of China (NMPA) has approved CanSino Biologics ’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster. This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version.

Vaccine 264

Vaccine Vaccination Genetic Engineering Clinical Trials 264

Bio Pharma Dive

SEPTEMBER 25, 2020

The Maryland-based biotech is the first developer to advance a more traditional protein-based vaccine into the final stages of clinical testing.

Vaccine 210

Vaccine Vaccination Protein Trials 210

Bio Pharma Dive

MAY 19, 2023

The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.

RNA 303

RNA Medicine Clinical Trials Clinical Trials 303

Pharmaceutical Technology

JUNE 24, 2022

As regulatory agencies gear up for another round of Covid-19 vaccine deliberations centered on emerging variants, Moderna has released data on its booster’s efficacy against Omicron subvariants. The mRNA-1273.214 booster contains the original Spikevax vaccine and a candidate targeting Omicron BA.1 1 variant of concern.

Vaccine 264

Vaccine Vaccination Antibody Medicine 264

Bio Pharma Dive

SEPTEMBER 23, 2024

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said CEO Emmanuel Hanon.

Vaccine 159

Vaccine Vaccination Protein Manufacturing 159

Pharmaceutical Technology

JULY 12, 2022

million doses of the company’s Covid-19 vaccine, NVX-CoV2373, in the initial stage. The order is contingent on the vaccine obtaining Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) as well as the Centers for Disease Control and Prevention (CDC) recommendation. The post US to procure 3.2

Vaccine 162

Vaccine Vaccination Protein Pharmacy 162

Pharmaceutical Technology

FEBRUARY 14, 2023

The US Department of Health and Human Services (HHS) and the Department of Defense have modified their existing agreement with Novavax to secure additional doses of the Covid-19 vaccine, Adjuvanted (NVX-CoV2373). million additional doses of its Covid-19 vaccine. Under the modified deal, Novavax will deliver up to 1.5

Vaccine 162

Vaccine Vaccination Protein Engineer 162

Pharmaceutical Technology

JUNE 7, 2024

Discover Curevac NV's groundbreaking patent for an mRNA-based RSV vaccine, targeting prophylaxis and treatment. Learn about the innovative pharmaceutical composition and method for stimulating a robust immune response against RSV.

Immune Response 130

Immune Response Vaccine Vaccination Protein 130

Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccine 246

Vaccine Vaccination Immune Response Protein 246

Medical Xpress

JANUARY 17, 2025

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby providing protection.

Antibody 143

Antibody Vaccine Vaccination Protein 143

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. There is an enormous emphasis on prion protein and prion protein folding,” says Dr. Laura Manuelidis, professor of neuropathology at the Yale School of Medicine. “If

Drugs 299

Drugs Protein Vaccine Vaccination 299

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. The post Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2 appeared first on.

Protein 122

Protein Immune Response Vaccine Vaccination 122

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 That analysis also showed that the Novavax COVID-19 vaccine was 96.4

Protein 97

Protein Vaccine Vaccination Trials 97

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

pharmaphorum

JANUARY 10, 2024

Novavax is a leading pharmaceutical company dedicated to creating protein-based vaccines for diseases like COVID-19 and malaria. Learn more about their innovative vaccine development process and their commitment to creating a healthier future.

Vaccine 124

Vaccine Vaccination Protein Development 124

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

Pharmaceutical Technology

SEPTEMBER 14, 2022

Novavax and Serum Institute of India (SII) have reported that the former’s Covid-19 vaccine, NVX-CoV2373, has received full product registration from the South African Health Products Regulatory Authority (SAHPRA), with conditions. The vaccine showed efficacy, with an encouraging safety and tolerability profile, in the trials. .

Vaccine 147

Vaccine Vaccination Clinical Trials Clinical Trials 147

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccine 145

Vaccine Vaccination Trials Immune Response 145

Pharmaceutical Technology

JULY 27, 2022

Novavax has r eceived expanded approval for provisional registration from the Australian Therapeutic Goods Agency (TGA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. It is the first protein-based vaccine to be offered in Australia for adolescents aged 12 to 17 years.

Vaccine 147

Vaccine Vaccination Clinical Trials Clinical Trials 147

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Based on the virus a number of vaccines targeting the spike protein were designed, tested in animal models and found to be quite promising against SARS and other coronavirus illnesses like Middle East respiratory syndrome.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Oncolytic viral proteins. Sillajen and Advaxis are the other key patent filers of oncolytic viral proteins.

Protein 130

Protein Gene Genetics Gene Therapy 130

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccine 162

Vaccine Vaccination Antibody Development 162

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

Medical Xpress

FEBRUARY 16, 2023

An adenovirus serotype 26 respiratory syncytial virus (RSV) vector encoding a prefusion F (preF) protein (Ad26.RSV.preF) RSV.preF) in combination with RSV preF protein is immunogenic and prevents RSV-mediated lower respiratory tract disease in older adults, according to a study published in the Feb.

Protein 89

Protein Vaccine Vaccination Medicine 89

Pharma Times

JULY 22, 2022

Molecular clamp technology is a protein tag that stabilises a wide range of complex viral proteins

Protein 142

Protein Development Vaccine Vaccination 142

pharmaphorum

JANUARY 12, 2021

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio. Non-injectables remove the need for health professional-led immunisation programmes, making widespread vaccine roll-outs quicker and easier and more affordable,” Channon told pharmaphorum.

Licensing 119

Licensing Licensing Vaccine Vaccination 119

Pharma Mirror

SEPTEMBER 11, 2022

Bandung, W Java, Indonesia, PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing of IndoVac, a Covid-19 vaccine brand it has developed since November 2021.

Vaccine 130

Vaccine Vaccination Clinical Trials Clinical Trials 130

NPR Health - Shots

JULY 19, 2022

The spike protein vaccine is more typical than the mRNA types being broadly used against COVID. Adults who haven't gotten any COVID-19 shots should consider the new option, the agency said Tuesday. Image credit: Georg Wendt/AP)

Vaccine 126

Vaccine Vaccination Protein 126

BioSpace

OCTOBER 26, 2021

Nuravax is developing a vaccine to induce therapeutically potent concentrations of antibodies against pathological proteins associated with both AD and Parkinson's disease.

Vaccine 116

Vaccine Vaccination Protein Antibody 116